|
ES2221717T3
(es)
|
1997-12-08 |
2005-01-01 |
Emd Lexigen Research Center Corp. |
Proteinas de fusion heterodimeras utiles para inmunoterapia dirigida e inmunoestimulacion general.
|
|
AU4057300A
(en)
|
1999-03-30 |
2000-10-16 |
Board Of Regents, The University Of Texas System |
Compositions and methods for modifying toxic effects of proteinacious compounds
|
|
US7067110B1
(en)
|
1999-07-21 |
2006-06-27 |
Emd Lexigen Research Center Corp. |
Fc fusion proteins for enhancing the immunogenicity of protein and peptide antigens
|
|
RU2263118C2
(ru)
|
1999-08-09 |
2005-10-27 |
Лексиген Фармасьютикэлс Корп. |
Комплексы антител с несколькими цитокинами
|
|
JP2003514552A
(ja)
|
1999-11-12 |
2003-04-22 |
メルク パテント ゲゼルシャフト ミット ベシュレンクテル ハフトング |
改善された性質を有するエリトロポエチンの形態
|
|
ATE336514T1
(de)
|
2000-02-11 |
2006-09-15 |
Merck Patent Gmbh |
Steigerung der zirkulierenden halbwertzeit von auf antikörpern basierenden fusionsproteinen
|
|
EP1935431A3
(de)
|
2000-05-15 |
2008-08-13 |
Health Research, Inc. |
Krebsbehandlungen unter Verwendung einer Kombination aus einem HER2-Antikörper und Interleukin-2
|
|
US6689353B1
(en)
*
|
2000-06-28 |
2004-02-10 |
Bayer Pharmaceuticals Corporation |
Stabilized interleukin 2
|
|
US7517526B2
(en)
|
2000-06-29 |
2009-04-14 |
Merck Patent Gmbh |
Enhancement of antibody-cytokine fusion protein mediated immune responses by combined treatment with immunocytokine uptake enhancing agents
|
|
MY139948A
(en)
*
|
2000-09-28 |
2009-11-30 |
Bayer Corp |
Enhanced transfection system
|
|
US7723102B2
(en)
*
|
2000-09-28 |
2010-05-25 |
Bayer Corporation |
Enhanced transfection system
|
|
PT1366067E
(pt)
|
2001-03-07 |
2012-11-29 |
Merck Patent Gmbh |
Tecnologia de expressão para proteínas contendo uma unidade de anticorpo de isotipo híbrido
|
|
US6992174B2
(en)
|
2001-03-30 |
2006-01-31 |
Emd Lexigen Research Center Corp. |
Reducing the immunogenicity of fusion proteins
|
|
DE60239454D1
(de)
|
2001-05-03 |
2011-04-28 |
Merck Patent Gmbh |
Rekombinanter, tumorspezifischer antikörper und dessen verwendung
|
|
AU2002357784B2
(en)
|
2001-12-04 |
2008-07-31 |
Merck Patent Gmbh |
Immunocytokines with modulated selectivity
|
|
ES2346205T3
(es)
|
2002-12-17 |
2010-10-13 |
Merck Patent Gmbh |
Anticuerpo humanizado (h14.18) del anticurpo 14.18 de raton que se enlaza con gd2 y su fusion con la il-2.
|
|
US7569215B2
(en)
|
2003-07-18 |
2009-08-04 |
Massachusetts Institute Of Technology |
Mutant interleukin-2 (IL-2) polypeptides
|
|
DE602004031341D1
(de)
*
|
2003-07-21 |
2011-03-24 |
Transgene Sa |
Multifunktionelle cytokine
|
|
CA2531773A1
(en)
|
2003-07-21 |
2005-02-17 |
Transgene S.A. |
Novel multifunctional cytokines
|
|
ATE473016T1
(de)
|
2003-11-04 |
2010-07-15 |
Novartis Vaccines & Diagnostic |
Verfahren zur behandlung von krebs mit expression des cd40-antigens
|
|
EP1718670B1
(de)
*
|
2004-02-27 |
2011-07-13 |
INSERM (Institut National de la Santé et de la Recherche Médicale) |
Il-15-bindungsstelle für il-15-ralpha und spezifische il-15-mutanten mit wirkung als agonisten/antagonisten
|
|
WO2005091956A2
(en)
*
|
2004-03-05 |
2005-10-06 |
Chiron Corporation |
In vitro test system for predicting patient tolerability of therapeutic agents
|
|
US8906356B2
(en)
|
2007-11-05 |
2014-12-09 |
Massachusetts Institute Of Technology |
Mutant interleukin-2 (IL-2) polypeptides
|
|
CN101244261B
(zh)
*
|
2008-03-10 |
2010-09-15 |
山东大学 |
一种含未复性重组蛋白的生物制剂及其制备方法与应用
|
|
DE102008023820A1
(de)
*
|
2008-05-08 |
2009-11-12 |
Aicuris Gmbh & Co. Kg |
Mittel zur Behandlung und/oder Prophylaxe einer Autoimmunerkrankung und zur Bildung von Regulatorischen T-Zellen
|
|
MX2011007647A
(es)
|
2009-01-21 |
2011-09-01 |
Amgen Inc |
Composiciones y metodos para el tratamiento de enfermedades inflamatorias y autoinmunes.
|
|
CN102101885B
(zh)
*
|
2010-09-01 |
2013-06-05 |
南京发士达生物科技有限公司 |
低诱导抑制性t细胞的人白细胞介素ⅱ突变体及其用途
|
|
HRP20210642T1
(hr)
|
2010-11-12 |
2021-05-28 |
Nektar Therapeutics |
Konjugati il-2 ostatka i polimera
|
|
CU23923B1
(es)
*
|
2010-11-12 |
2013-07-31 |
Ct De Inmunología Molecular |
Polipéptidos derivados de la il-2 con actividad agonista
|
|
US9428567B2
(en)
|
2010-12-22 |
2016-08-30 |
The Board Of Trustees Of The Leland Stanford Junior University |
Antagonists of interleukin-2 receptor
|
|
LT3075745T
(lt)
|
2011-02-10 |
2018-11-26 |
Roche Glycart Ag |
Mutavę interleukino-2 polipeptidai
|
|
WO2012119093A1
(en)
*
|
2011-03-03 |
2012-09-07 |
Board Of Trustees Of The Leland Stanford Junior University |
Superagonists and antagonists of interleukin-2
|
|
EA201892619A1
(ru)
|
2011-04-29 |
2019-04-30 |
Роше Гликарт Аг |
Иммуноконъюгаты, содержащие мутантные полипептиды интерлейкина-2
|
|
US20140044675A1
(en)
|
2012-08-10 |
2014-02-13 |
Roche Glycart Ag |
Interleukin-2 fusion proteins and uses thereof
|
|
CA2925421C
(en)
|
2013-09-24 |
2023-08-29 |
Medicenna Therapeutics, Inc. |
Interleukin-2 fusion proteins and uses thereof
|
|
RS58149B1
(sr)
|
2014-02-06 |
2019-02-28 |
Hoffmann La Roche |
Fuzioni proteini interleukina-2 i njihova upotreba
|
|
GB201403775D0
(en)
|
2014-03-04 |
2014-04-16 |
Kymab Ltd |
Antibodies, uses & methods
|
|
WO2015164815A1
(en)
|
2014-04-24 |
2015-10-29 |
The Board Of Trustees Of The Leland Stanford Junior University |
Superagonists, partial agonists and antagonists of interleukin-2
|
|
MA40094B1
(fr)
|
2014-08-06 |
2022-05-31 |
Univ Miami |
Protéines de fusion de l'interleukine-2/récepteur alpha de l'interleukine-2 et procédés d'utilisation
|
|
ES2807260T3
(es)
|
2014-08-11 |
2021-02-22 |
Delinia Inc |
Variantes de IL-2 modificadas que activan selectivamente las células T reguladoras para el tratamiento de enfermedades autoinmunes
|
|
WO2016164937A2
(en)
*
|
2015-04-10 |
2016-10-13 |
Amgen Inc. |
Interleukin-2 muteins for the expansion of t-regulatory cells
|
|
KR102861230B1
(ko)
|
2015-10-08 |
2025-09-17 |
넥타르 테라퓨틱스 |
Il-2r베타-선택적 효현제 및 지속 작용성 il-15 효현제의 조합
|
|
US20170204154A1
(en)
|
2016-01-20 |
2017-07-20 |
Delinia, Inc. |
Molecules that selectively activate regulatory t cells for the treatment of autoimmune diseases
|
|
EP3458485B1
(de)
|
2016-05-19 |
2021-12-29 |
The General Hospital Corporation |
An den rezeptor il-2rbeta gebundenes interleukin-2, eine plattform zur erhöhung der aktivität von natürlichen killer- und regulatorischen t-zellen
|
|
KR102379464B1
(ko)
|
2016-06-20 |
2022-03-29 |
키맵 리미티드 |
항-pd-l1 항체
|
|
US9567399B1
(en)
|
2016-06-20 |
2017-02-14 |
Kymab Limited |
Antibodies and immunocytokines
|
|
ES2988783T3
(es)
*
|
2016-06-22 |
2024-11-21 |
David Klatzmann |
Linfocitos T genéticamente modificados
|
|
EP3534947A1
(de)
|
2016-11-03 |
2019-09-11 |
Kymab Limited |
Antikörper, kombinationen mit antikörpern, biomarker, verwendungen und verfahren
|
|
CN110167957A
(zh)
|
2016-11-08 |
2019-08-23 |
德里尼亚公司 |
用于治疗自身免疫疾病的il-2变体
|
|
BR112019011799B1
(pt)
*
|
2016-12-13 |
2021-12-21 |
Delinia, Inc |
Proteína de fusão, proteína dimérica e composição farmacêutica
|
|
BR112019018915A2
(pt)
|
2017-03-15 |
2020-04-14 |
Pandion Therapeutics Inc |
imunotolerância direcionada
|
|
SG11201909949XA
(en)
|
2017-05-24 |
2019-11-28 |
Pandion Therapeutics Inc |
Targeted immunotolerance
|
|
CN111107868A
(zh)
*
|
2017-05-24 |
2020-05-05 |
诺华股份有限公司 |
抗体细胞因子移植蛋白及使用方法
|
|
JP7791642B2
(ja)
|
2017-05-24 |
2025-12-24 |
ノバルティス アーゲー |
抗体－サイトカイングラフト化タンパク質及び癌の治療における使用方法
|
|
JOP20190271A1
(ar)
|
2017-05-24 |
2019-11-21 |
Novartis Ag |
بروتينات مطعّمة بسيتوكين- الجسم المضاد وطرق الاستخدام للاضطرابات المتعلقة بالمناعة
|
|
JP7433051B2
(ja)
|
2017-06-19 |
2024-02-19 |
メディシナ セラピューティクス インコーポレイテッド |
Ｉｌ－２スーパーアゴニスト、アゴニスト、およびそれらの融合体の使用および方法
|
|
KR20250145137A
(ko)
*
|
2017-08-03 |
2025-10-13 |
신톡스, 인크. |
자가면역 질환의 치료를 위한 사이토카인 접합체
|
|
PH12020550661A1
(en)
*
|
2017-11-21 |
2021-04-19 |
Univ Leland Stanford Junior |
Partial agonists of interleukin-2
|
|
US10946068B2
(en)
|
2017-12-06 |
2021-03-16 |
Pandion Operations, Inc. |
IL-2 muteins and uses thereof
|
|
US10174092B1
(en)
|
2017-12-06 |
2019-01-08 |
Pandion Therapeutics, Inc. |
IL-2 muteins
|
|
USRE50550E1
(en)
|
2017-12-06 |
2025-08-26 |
Pandion Operations, Inc. |
IL-2 muteins and uses thereof
|
|
IL275426B2
(en)
|
2017-12-19 |
2025-03-01 |
Xencor Inc |
Engineered il-2 fc fusion proteins
|
|
WO2019158764A1
(en)
|
2018-02-16 |
2019-08-22 |
Iltoo Pharma |
Use of interleukin 2 for treating sjögren's syndrome
|
|
MX2020009975A
(es)
|
2018-03-28 |
2020-10-12 |
Bristol Myers Squibb Co |
Proteinas de fusion interleucina-2/receptor alfa de interleucina-2 y metodos de uso.
|
|
KR20200139730A
(ko)
|
2018-03-28 |
2020-12-14 |
아센디스 파마 온콜로지 디비전 에이/에스 |
Il-2 접합체
|
|
WO2020007937A1
(en)
|
2018-07-03 |
2020-01-09 |
Iltoo Pharma |
Use of interleukin-2 for treating systemic sclerosis
|
|
JP7550745B2
(ja)
*
|
2018-07-24 |
2024-09-13 |
バイオエヌテック エスエー |
Ｉｌ２アゴニスト
|
|
WO2020035482A1
(en)
|
2018-08-13 |
2020-02-20 |
Iltoo Pharma |
Combination of interleukin-2 with an interleukin 1 inhibitor, conjugates and therapeutic uses thereof
|
|
CN111971295B
(zh)
|
2018-09-17 |
2024-08-02 |
Gi医诺微新 |
包含il-2蛋白和cd80蛋白的融合蛋白及其用途
|
|
TWI801664B
(zh)
|
2018-09-21 |
2023-05-11 |
大陸商信達生物製藥（蘇州）有限公司 |
新型白介素２及其用途
|
|
TWI791894B
(zh)
|
2018-09-21 |
2023-02-11 |
大陸商信達生物製藥（蘇州）有限公司 |
新型白介素２及其用途
|
|
EP3875475A4
(de)
|
2018-12-21 |
2022-12-07 |
Jiangsu Hengrui Pharmaceuticals Co., Ltd. |
Humane interleukin-2-variante oder derivat davon
|
|
US11739146B2
(en)
|
2019-05-20 |
2023-08-29 |
Pandion Operations, Inc. |
MAdCAM targeted immunotolerance
|
|
TW202115105A
(zh)
*
|
2019-06-24 |
2021-04-16 |
德商拜恩迪克Ｒｎａ製藥有限公司 |
Ｉｌ２激動劑
|
|
AU2020323893A1
(en)
|
2019-07-26 |
2022-02-17 |
Visterra, Inc. |
Interleukin-2 agents and uses thereof
|
|
AU2020328038B2
(en)
*
|
2019-08-13 |
2025-10-09 |
Amgen Inc. |
Interleukin-2 muteins for the expansion of T-regulatory cells
|
|
KR20220139293A
(ko)
|
2019-12-12 |
2022-10-14 |
일투 파마 |
인터류킨 2 키메라 구축물
|
|
MX2022007712A
(es)
|
2019-12-17 |
2022-09-26 |
Amgen Inc |
Agonista doble de interleucina-2/receptor de tnf para uso en terapia.
|
|
AU2021206449A1
(en)
|
2020-01-10 |
2022-07-21 |
Bright Peak Therapeutics Ag |
Modified IL-2 polypeptides and uses thereof
|
|
US20230210951A1
(en)
*
|
2020-01-14 |
2023-07-06 |
Synthekine, Inc. |
Il2 muteins
|
|
EP4090674A4
(de)
|
2020-01-14 |
2024-01-24 |
Synthekine, Inc. |
Vorgespannte il2-muteins-verfahren und -zusammensetzungen
|
|
US11981715B2
(en)
|
2020-02-21 |
2024-05-14 |
Pandion Operations, Inc. |
Tissue targeted immunotolerance with a CD39 effector
|
|
AU2021239225B2
(en)
|
2020-03-19 |
2024-08-15 |
Fortvita Biologics (Singapore) Pte.Ltd. |
Interleukin-2 mutant and use thereof
|
|
JP2023515247A
(ja)
*
|
2020-03-31 |
2023-04-12 |
ハンミ ファーマシューティカル カンパニー リミテッド |
新規な免疫活性インターロイキン２アナログ
|
|
IL298642A
(en)
|
2020-06-03 |
2023-01-01 |
Ascendis Pharma Oncology Div A/S |
il-2 sequences and uses thereof
|
|
CN114507643A
(zh)
*
|
2020-10-29 |
2022-05-17 |
未来智人再生医学研究院(广州)有限公司 |
一种表达il-2的多能干细胞衍生物及应用
|
|
CA3195260A1
(en)
|
2020-10-29 |
2022-05-05 |
Bristol-Myers Squibb Company |
Fusion proteins for the treatment of disease
|
|
TW202237171A
(zh)
|
2020-12-04 |
2022-10-01 |
美商威特拉公司 |
使用介白素-2藥劑之方法
|
|
CN113308477A
(zh)
*
|
2021-04-08 |
2021-08-27 |
华南农业大学 |
一种鸭il-2基因真核表达重组质粒及其制备方法
|
|
AU2022350407B2
(en)
|
2021-09-22 |
2025-09-04 |
Fortvita Biologics (Singapore) Pte. Ltd. |
Interleukin-2 mutant and fusion protein thereof
|
|
US20240376172A1
(en)
|
2021-10-06 |
2024-11-14 |
Iltoo Pharma |
Interleukin 2 chimeric constructs with targeting specificy to inflamed tissues
|
|
CN114875069B
(zh)
*
|
2022-04-22 |
2023-09-15 |
四川大学 |
基因工程修饰的il2细胞因子的重组载体、宿主细胞及其用途
|
|
PE20250753A1
(es)
*
|
2022-06-16 |
2025-03-13 |
Cephalon Llc |
Inmunoconjugados de il-2 atenuada-anticuerpo anti-pd-1 y usos de los mismos
|
|
AU2022477937A1
(en)
|
2022-09-12 |
2025-04-10 |
Assistance Publique - Hôpitaux De Paris |
Interleukin-2 for use in treating autism spectrum disorder
|
|
FR3140287B1
(fr)
|
2022-10-03 |
2025-11-21 |
Arkema France |
Procede de granulation de composes azoiques et granules obtenus
|
|
EP4631972A1
(de)
|
2022-11-18 |
2025-10-15 |
Nanjing Novoacine Biotechnology Co., Ltd. |
Ortsspezifisch gekoppelter pegylierter interleukin-2-mutant mit rezeptoraffinitätspräferenz und verwendung davon
|